ReviewNeuropsychiatric disease and treatment2017
The role of deep brain stimulation in Parkinson's disease: an overview and update on new developments.
Review in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- Article
- Continuous Accelerometry-Based Tremor Detection During Daily Living.Sensors (Basel, Switzerland) · 2026Article
- Article
- The impact of sociodemographic factors and surgical modalities on deep brain stimulation for Parkinson's disease.Surgical neurology international · 2025Article
- Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson's disease.Frontiers in cellular neuroscience · 2025Review
- Theta and beta power in the subthalamic nucleus responds to conflict across subregions and hemispheres.Brain communications · 2025Article
- Best practices for clinical trials of deep brain stimulation for neuropsychiatric indications.Frontiers in human neuroscience · 2025Article
- Inspiring a convergent engineering approach to measure and model the tissue microenvironment.Heliyon · 2024Review
- Comparison of the Long-Term Efficacy of Targeting the Subthalamic Nucleus Versus the Globus Pallidus Interna for Deep Brain Stimulation Treatment of Motor Dysfunction in Patients With Parkinson's Disease: A Meta-Analysis Study.Parkinson's disease · 2024Review
- Beyond Tissue replacement: The Emerging role of smart implants in healthcare.Materials today. Bio · 2023Review
- Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges.APL bioengineering · 2023Review
- Review
- Protocol of a randomized controlled trial investigating Deep Brain Stimulation for MOtor symptoms in patients with Parkinson's disease DEmentia (DBS-MODE).BMC neurology · 2023Article
- Wireless and battery-free technologies for neuroengineering.Nature biomedical engineering · 2023Review
- Deep Brain Stimulation of the Interposed Cerebellar Nuclei in a Conditional Genetic Mouse Model with Dystonia.Advances in neurobiology · 2023Article
- Stereotactic Staged Asymmetric Bilateral Radiofrequency Lesioning for Parkinson's Disease.Stereotactic and functional neurosurgery · 2023Article
- Monitoring time domain characteristics of Parkinson's disease using 3D memristive neuromorphic system.Frontiers in computational neuroscience · 2023Article
- Effects of deep brain stimulation target on the activation and suppression of action impulses.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2022Article
- Deep brain stimulation for Parkinson's Disease: A Review and Future Outlook.Biomedical engineering letters · 2022Review
- An unusual presentation of convergence insufficiency in a patient with Parkinson's disease stimulated by deep brain stimulation.American journal of ophthalmology case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of neuronal dopamine production in the brain. Oral therapies primarily augment the dopaminergic pathway. As the disease progresses, more continuous delivery of therapy is commonly needed. Deep brain stimulation (DBS) has become an effective therapy option for several different neurologic and psychiatric conditions, including PD. It currently has US Food and Drug Administration approval for PD and essential tremor, as well as a humanitarian device exception for dystonia and obsessive-compulsive disorder. For PD treatment, it is currently approved specifically for those patients suffering from complications of pharmacotherapy, including motor fluctuations or dyskinesias, and a disease process of at least 4 years of duration. Studies have demonstrated superiority of DBS and medical management compared to medical management alone in selected PD patients. Optimal patient selection criteria, choice of target, and programming methods for PD and the other indications for DBS are important topics that continue to be explored and remain works in progress. In addition, new hardware options, such as different types of leads, and different software options have recently become available, increasing the potential for greater efficacy and/or reduced side effects. This review gives an overview of therapeutic management in PD, specifically highlighting DBS and some of the recent changes with surgical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.